Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 3, 2026, 5:15 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 57 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Cohort B3 Clear all
Completed Phase 1 Interventional Results available

A Dose Escalation and Expansion Study of Lomvastomig, a PD-1/TIM-3 Bispecific Antibody, in Participants With Advanced and/or Metastatic Solid Tumors

NCT03708328
View directory record Official record
Conditions
Solid Tumors, Metastatic Melanoma, Non-small Cell Lung Cancer (NSCLC), Small Cell Lung Cancer (SCLC), Esophageal Squamous Cell Carcinoma (ESCC)
Interventions
Lomvastomig
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
134 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
2
States / cities
New York, New York • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 19, 2025 · Synced Sep 3, 2026, 5:15 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

First To Know Pregnancy Test - Clinical Evaluation Protocol

NCT07304531
View directory record Official record
Conditions
Pregnancy Detection
Interventions
Diagnostic Test
Device
Lead sponsor
NOWDiagnostics, Inc.
Industry
Eligibility
14 Years and older · Female only
Enrollment
1,705 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
2
States / cities
Los Angeles, California • Midland, Texas
Source: ClinicalTrials.gov public record
Updated Dec 25, 2025 · Synced Sep 3, 2026, 5:15 AM EDT
Completed Phase 1 Interventional

Safety Study of AMG 386 to Treat HER2-positive Locally Recurrent or Metastatic Breast Cancer

NCT00807859
View directory record Official record
Conditions
Breast Cancer, Breast Neoplasms, Breast Tumors, Cancer, Locally Recurrent and Metastatic Breast Cancer, Metastases, Metastatic Cancer, Oncology, Solid Tumors, Tumors
Interventions
AMG 386 30 mg/kg, Paclitaxel and Trastuzumab, AMG 386 30 mg/kg, Capecitabine and Lapatinib, AMG 386 10 mgkg, Paclitaxel and Trastuzumab, AMG 386 10 mg/kg, Capecitabine and Lapatinib
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older · Female only
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
13
States / cities
Tucson, Arizona • Boca Raton, Florida • Iowa City, Iowa + 9 more
Source: ClinicalTrials.gov public record
Updated Nov 7, 2022 · Synced Sep 3, 2026, 5:15 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Safety and Pharmacokinetics of AT-007 in Healthy Subjects and in Adult Subjects With Classic Galactosemia

NCT04117711
View directory record Official record
Conditions
Classic Galactosemia
Interventions
AT-007, Placebo
Drug
Lead sponsor
Applied Therapeutics, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
114 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
4
States / cities
Anaheim, California • Atlanta, Georgia • Boston, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated May 29, 2024 · Synced Sep 3, 2026, 5:15 AM EDT
Completed Phase 1 Interventional

A Study To Investigate The Pharmacokinetics, Safety, And Tolerability Of Subcutaneous Ocrelizumab Administration In Participants With Multiple Sclerosis

NCT03972306
View directory record Official record
Conditions
Multiple Sclerosis (MS)
Interventions
Ocrelizumab, rHuPH20
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 65 Years
Enrollment
134 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
18
States / cities
Aurora, Colorado • Washington D.C., District of Columbia • Alexandria, Louisiana + 15 more
Source: ClinicalTrials.gov public record
Updated Jul 7, 2025 · Synced Sep 3, 2026, 5:15 AM EDT
Recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

A Study of RM-718 in Healthy Subjects and Patients With MC4R Pathway Impairment

NCT06239116
View directory record Official record
Conditions
Hypothalamic Obesity, Prader-Willi Syndrome, PWS
Interventions
Part A: RM-718 or placebo (matched to specific RM-718 dose cohort), Part B: RM-718 or placebo (matched to specific RM-718 dose cohort), Part C: RM-718, Part D: RM-718
Drug
Lead sponsor
Rhythm Pharmaceuticals, Inc.
Industry
Eligibility
12 Years to 65 Years
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2028
U.S. locations
7
States / cities
Birmingham, Alabama • Chicago, Illinois • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Dec 21, 2025 · Synced Sep 3, 2026, 5:15 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A First-in-Human Study of SBP-9330 in Healthy Subjects

NCT04948827
View directory record Official record
Conditions
Smoking Cessation
Interventions
SBP-9330, Placebo
Drug
Lead sponsor
Camino Pharma, LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Apr 15, 2024 · Synced Sep 3, 2026, 5:15 AM EDT
Terminated Phase 1 Interventional Results available

A Study Evaluating The Safety, Tolerability, Pharmacokinetics, And Efficacy Of Venetoclax In Combination With Atezolizumab, Carboplatin, And Etoposide In Participants With Untreated Extensive-Stage Small Cell Lung Cancer (ES-SCLC).

NCT04422210
View directory record Official record
Conditions
Small Cell Lung Cancer
Interventions
Venetoclax, Atezolizumab, Carboplatin, Etoposide
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Nov 7, 2021 · Synced Sep 3, 2026, 5:15 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Lu AF82422 in Healthy Non-Japanese and Japanese Subjects and in Patients With Parkinson's Disease

NCT03611569
View directory record Official record
Conditions
Healthy, Parkinson Disease
Interventions
Lu AF82422, Placebo
Drug
Lead sponsor
H. Lundbeck A/S
Industry
Eligibility
18 Years to 80 Years
Enrollment
74 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
4
States / cities
Glendale, California • Hollywood, Florida • Orlando, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 11, 2021 · Synced Sep 3, 2026, 5:15 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

A Study Of The Selective PKC-β Inhibitor MS- 553

NCT03492125
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Aggressive Lymphoma
Interventions
MS-553, acalabrutinib, venetoclax, Rituximab, obinutuzumab
Drug
Lead sponsor
MingSight Pharmaceuticals, Inc
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
5
States / cities
Ann Arbor, Michigan • New York, New York • Columbus, Ohio + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 9, 2025 · Synced Sep 3, 2026, 5:15 AM EDT
Terminated Phase 1 Interventional

Hepatic Arterial Infusion in Treating Patients With Locally Advanced, Non-Metastatic Cholangiocarcinoma

NCT01525069
View directory record Official record
Conditions
Cholangiocarcinoma, Liver Neoplasms
Interventions
Floxuridine, Dexamethasone, Gemcitabine, Oxaliplatin
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2022
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Aug 9, 2022 · Synced Sep 3, 2026, 5:15 AM EDT
Not yet recruiting Phase 1 Interventional

Study of Supplemental Arginine With Chemotherapy and Immunotherapy in Platinum Resistant Ovarian, Fallopian Tube, and Peritoneal Cancer

NCT07772882
View directory record Official record
Conditions
Platinum Resistant Ovarian Cancer, Fallopian Tube Cancers, Peritoneal Carcinoma
Interventions
Cohort A1, Cohort A2, Cohort A3, A3 Expansion, Cohort B1, Cohort B2, Cohort B3, B3 Expansion
Drug
Lead sponsor
Rebecca Arend
Other
Eligibility
18 Years to 89 Years · Female only
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Sep 3, 2026, 5:15 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study With Lu AF87908 in Healthy Participants and Participants With Alzheimer's Disease

NCT04149860
View directory record Official record
Conditions
Healthy, Alzheimer Disease
Interventions
Lu AF87908, Placebo
Drug
Lead sponsor
H. Lundbeck A/S
Industry
Eligibility
18 Years to 65 Years
Enrollment
86 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2023
U.S. locations
6
States / cities
Glendale, California • Hollywood, Florida • Miami, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 3, 2023 · Synced Sep 3, 2026, 5:15 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

IV Administration of ChromaDex's Niagen® as Compared to NAD+

NCT06382688
View directory record Official record
Conditions
Healthy Aging
Interventions
NAD+ (nicotinamide adenine dinucleotide) IV, Niagen® (nicotinamide riboside) IV, Niagen® (nicotinamide riboside) oral, Placebo
Dietary Supplement · Other
Lead sponsor
Nutraceuticals Research Institute
Other
Eligibility
40 Years and older
Enrollment
53 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Franklin, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 23, 2024 · Synced Sep 3, 2026, 5:15 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Look at How Safe a New Medicine (NNC0491-6075) is in Healthy People and in Participants With High Levels of Fat in the Blood

NCT05979428
View directory record Official record
Conditions
Healthy Volunteers, Dyslipidaemia
Interventions
NNC0491-6075, Placebo
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 55 Years
Enrollment
106 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Sep 3, 2026, 5:15 AM EDT
Active, not recruiting Phase 2 Interventional Results available

Phase II Umbrella Study of Novel Anti-cancer Agents in Participants With NSCLC Who Progressed on an Anti-PD-1/PD-L1 Containing Therapy

NCT03334617
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
Durvalumab, Danvatirsen, Ceralasertib, Vistusertib, Olaparib, Oleclumab, Trastuzumab deruxtecan, Cediranib
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 99 Years
Enrollment
528 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
17
States / cities
Duarte, California • Fullerton, California • La Jolla, California + 12 more
Source: ClinicalTrials.gov public record
Updated Oct 26, 2025 · Synced Sep 3, 2026, 5:15 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Phase 1 Study of LQT-1213 in Healthy Adults

NCT05759962
View directory record Official record
Conditions
Long QT Syndrome
Interventions
LQT-1213, Placebo
Drug · Other
Lead sponsor
Thryv Therapeutics, Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated Sep 25, 2023 · Synced Sep 3, 2026, 5:15 AM EDT
Terminated Phase 1 Interventional Results available

A Phase I/II Study of AZD0466 as Monotherapy or in Combination With Anticancer Agents in Advanced Non-Hodgkin Lymphoma

NCT05205161
View directory record Official record
Conditions
Non-Hodgkin Lymphoma
Interventions
AZD0466
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Jan 6, 2025 · Synced Sep 3, 2026, 5:15 AM EDT
Completed Phase 1 Interventional

Phase I Study of U3P1287/01, Including Patients With Advanced Solid Tumors

NCT00730470
View directory record Official record
Conditions
Advanced Solid Tumors
Interventions
U3-1287 (AMG888)
Drug
Lead sponsor
U3 Pharma GmbH
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
6
States / cities
Boston, Massachusetts • Detroit, Michigan • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2010 · Synced Sep 3, 2026, 5:15 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Open-label Study to Assess Increasing Levels of NAD+(Nicotinamide Adenine Dinucleotide)

NCT03707652
View directory record Official record
Conditions
Increase in Blood Levels of Nicotinamide Adenine Dinucleotide (NAD+)
Interventions
Oral supplement A, Oral supplement B, Oral supplement C, Oral supplement D, Oral Supplement D in combination with oral supplement C
Dietary Supplement
Lead sponsor
Supplement Formulators, Inc.
Industry
Eligibility
30 Years to 80 Years
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Fort Lauderdale, Florida
Source: ClinicalTrials.gov public record
Updated Oct 17, 2018 · Synced Sep 3, 2026, 5:15 AM EDT
Active, not recruiting Early Phase 1 Interventional

AB154 Combined With AB122 for Recurrent Glioblastoma

NCT04656535
View directory record Official record
Conditions
Glioblastoma
Interventions
Zimberelimab, Domvanalimab, Placebo
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
3
States / cities
San Francisco, California • New Haven, Connecticut • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 16, 2026 · Synced Sep 3, 2026, 5:15 AM EDT
Completed Phase 1 Interventional

A Study to Investigate the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of RO7248824 in Participants With Angelman Syndrome (AS)

NCT04428281
View directory record Official record
Conditions
Angelman Syndrome
Interventions
RO7248824
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
1 Year to 12 Years
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
7
States / cities
Los Angeles, California • San Diego, California • Chicago, Illinois + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 23, 2025 · Synced Sep 3, 2026, 5:15 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

SAD and MAD Study of FTX-101 in Healthy Male Subjects

NCT06617546
View directory record Official record
Conditions
Healthy Volunteers
Interventions
FTX-101, Placebo
Drug
Lead sponsor
Find Therapeutics
Industry
Eligibility
18 Years to 59 Years · Male only
Enrollment
49 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Jun 17, 2025 · Synced Sep 3, 2026, 5:15 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study in Healthy Volunteers to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CS0159

NCT05082779
View directory record Official record
Conditions
Primary Sclerosing Cholangitis (PSC)
Interventions
CS0159
Drug
Lead sponsor
Cascade Pharmaceuticals, Inc
Other
Eligibility
18 Years to 55 Years
Enrollment
79 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Daytona Beach, Florida
Source: ClinicalTrials.gov public record
Updated Oct 17, 2022 · Synced Sep 3, 2026, 5:15 AM EDT